The Inflation Reduction Act of 2022 is a landmark United States federal law which aims to curb inflation by, among other things, lowering prescription drug prices. What can this mean for biopharmaceutical companies?
Dennis Kim, Senior Engagement Manager and Em Coriale, Director in the Value & Access team at Syneos Health, dive into the details of this piece of legislation, the true meaning of “unjustified price increases,” what negotiation might look like and how companies can prepare for the new reality.
For additional insights on the Inflation Reduction Act from our Reputation & Risk Management team, visit our blog.
The views expressed in this podcast belong solely to the speakers and do not represent those of their organization.
